(-)-dibenzyl trans-cyclohexane-1,3-diylbiscarbamate | 860296-80-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (-)-dibenzyl trans-cyclohexane-1,3-diylbiscarbamate
• 英文别名: benzyl N-[(1R,3R)-3-(phenylmethoxycarbonylamino)cyclohexyl]carbamate
• CAS: 860296-80-6
• 化学式: C₂₂H₂₆N₂O₄
• 分子量: 382.459
• InChiKey: UEBNNFJJFCKAFD-WOJBJXKFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  76.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氯-6-甲氧基-4-甲基-喹啉 、 (-)-dibenzyl trans-cyclohexane-1,3-diylbiscarbamate 在 palladium diacetate caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 生成
  参考文献：
  名称：

  Discovery of cyclopentane- and cyclohexane-trans-1,3-diamines as potent melanin-concentrating hormone receptor 1 antagonists

  摘要：

  We herein report the optimization of cyclopentane- and cyclohexane-1,3-diamine derivatives as novel and potent MCH-R I antagonists. Structural modifications of the 2-amino-quinoline and thiophene moieties found in the initial lead compound served to improve its metabolic stability profile and MCH-RI affinity, and revealed unprecedented SAR when compared to other 2-aminoquinoline-containing NICH-R1 antagonists. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.034
• 作为产物：
  描述：

  dibenzyl trans-cyclohexane-1,3-diylbiscarbamate 以99.3%的产率得到
  参考文献：
  名称：

  [EN] THERAPEUTIC AGENTS II
  [FR] AGENTS THERAPEUTIQUES II

  摘要：

  公式(I)的化合物及其光学异构体和外消旋体以及药学上可接受的盐，制备这些化合物的过程，它们在肥胖症、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫和相关疾病以及神经系统疾病，如痴呆、多发性硬化症、帕金森病、亨廷顿舞蹈症和阿尔茨海默病以及与疼痛相关的疾病的治疗中的应用，以及包含它们的制药组合物。

  公开号：

  WO2005070902A1

文献信息

• Therapeutic agents I
  申请人：Evertsson Emma

  公开号：US20070185079A1

  公开（公告）日：2007-08-09

  Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.

  化合物的公式(I)，制备这些化合物的过程，它们在治疗肥胖症、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫和相关疾病以及神经系统疾病如痴呆、多发性硬化症、帕金森病、亨廷顿舞蹈症和阿尔茨海默病以及与疼痛有关的疾病中的应用，以及含有它们的制药组合物。
• Discovery of cyclopentane- and cyclohexane-trans-1,3-diamines as potent melanin-concentrating hormone receptor 1 antagonists
  作者：Fabrizio Giordanetto、Olle Karlsson、Jan Lindberg、Lars-Olof Larsson、Anna Linusson、Emma Evertsson、David G.A. Morgan、Tord Inghardt

  DOI：10.1016/j.bmcl.2007.05.034

  日期：2007.8

  We herein report the optimization of cyclopentane- and cyclohexane-1,3-diamine derivatives as novel and potent MCH-R I antagonists. Structural modifications of the 2-amino-quinoline and thiophene moieties found in the initial lead compound served to improve its metabolic stability profile and MCH-RI affinity, and revealed unprecedented SAR when compared to other 2-aminoquinoline-containing NICH-R1 antagonists. (c) 2007 Elsevier Ltd. All rights reserved.
• [EN] THERAPEUTIC AGENTS II<br/>[FR] AGENTS THERAPEUTIQUES II
  申请人：ASTRAZENECA AB

  公开号：WO2005070902A1

  公开（公告）日：2005-08-04

  Compounds of Formula (I) as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.

  公式(I)的化合物及其光学异构体和外消旋体以及药学上可接受的盐，制备这些化合物的过程，它们在肥胖症、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫和相关疾病以及神经系统疾病，如痴呆、多发性硬化症、帕金森病、亨廷顿舞蹈症和阿尔茨海默病以及与疼痛相关的疾病的治疗中的应用，以及包含它们的制药组合物。